Atricure, Inc. insider trading
Every open-market purchase and sale by Atricure, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Atricure, Inc.’s insiders pay?
From June 15, 2010 to September 14, 2026, 33 insiders reported 27 open-market purchases and 101 sales not made under a pre-set plan in Atricure, Inc. Twelve months after each purchase was reported, the shares were +13.2% against the S&P 500 on average (median +12.2%), over 27 purchases with a full year of prices; 67% beat the index. After sales, the shares moved +4.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on November 3, 2010 into $240,287 by November 2, 2026, +22.0% a year. It held shares 46% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $32,766 (+7.7% a year), and held throughout $83,521 (+14.2%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Discovery Group I, LLC | 10% owner | 9 | −0.4% (9) | 44% | 4 | +84.3% (4) | December 19, 2012 |
| Krell Elizabeth D | Director | 0 | — | — | 12 | +1.3% (12) | May 9, 2018 |
| Donoghue Daniel J | 10% owner | 8 | −7.0% (8) | 50% | 3 | +1.3% (3) | November 28, 2012 |
| Drachman David J | President and CEO | 0 | — | — | 8 | −5.3% (8) | September 13, 2012 |
| Seith Douglas J | Chief Operating Officer | 2 | +38.3% (2) | 100% | 6 | −14.8% (6) | September 15, 2021 |
| Groves Regina E | Director | 2 | +50.5% (2) | 100% | 5 | −4.3% (4) | September 14, 2026 |
| Lucky James L | VP, Clinical, Regulatory & QS | 0 | — | — | 7 | +4.3% (7) | March 7, 2013 |
| Doraiswamy Vinayak | Chief Scientific Officer | 0 | — | — | 6 | −23.4% (3) | July 30, 2026 |
| Johnston Richard M | Director | 0 | — | — | 6 | +7.9% (6) | June 13, 2013 |
| Wehrwein Sven | Director | 0 | — | — | 5 | −5.8% (3) | July 30, 2026 |
| Murphy Michael R | 10% owner | 1 | +12.2% (1) | 100% | 3 | +49.6% (3) | December 13, 2012 |
| Prange Karen | Director | 0 | — | — | 4 | −57.8% (2) | August 7, 2026 |
| Yuen Maggie | Director | 0 | — | — | 4 | −17.7% (2) | August 7, 2026 |
| Drake Scott William | Director | 2 | +50.9% (2) | 100% | 1 | −42.1% (1) | May 11, 2021 |
| Hooven Michael D | Director | 0 | — | — | 3 | −13.2% (3) | February 23, 2017 |
| Noznesky Justin J | Chief Mktg & Strategy Officer | 0 | — | — | 3 | +48.8% (1) | July 30, 2026 |
| Privitera Salvatore | Chief Technical Officer | 1 | +41.7% (1) | 100% | 2 | +34.3% (2) | May 31, 2024 |
| Robards Karen P | Director | 0 | — | — | 3 | −16.7% (3) | May 8, 2015 |
| Hughes Donald W | Director | 0 | — | — | 2 | +82.0% (2) | June 20, 2013 |
| Lux Andrew L | SVP, Ops & Quality | 0 | — | — | 2 | −14.7% (2) | March 21, 2017 |
| Preiss Frederick | Vice President Operations | 0 | — | — | 2 | −36.8% (2) | June 16, 2011 |
| Berkeley Richard M | Director | 0 | — | — | 1 | +39.1% (1) | July 15, 2013 |
| Camden Partners Strategic Fund II A LP | Director | 0 | — | — | 1 | +83.0% (1) | June 19, 2013 |
| Camden Partners Strategic Fund II B LP | Director | 0 | — | — | 1 | +46.2% (1) | August 6, 2013 |
| Camden Partners Strategic II LLC | Director | 0 | — | — | 1 | +21.3% (1) | September 16, 2013 |
| Collar Mark A | Director | 0 | — | — | 1 | −8.9% (1) | June 18, 2018 |
| Dahlquist Karl S. | Chief Legal Officer | 0 | — | — | 1 | — | August 26, 2026 |
| Harrison Donald C | Director | 0 | — | — | 1 | +1.2% (1) | February 25, 2011 |
| Johnson B Kristine | Director | 1 | +58.8% (1) | 100% | 0 | — | November 9, 2017 |
| Lanning Mark R | Director | 1 | +24.1% (1) | 100% | 0 | — | September 14, 2012 |
| Piton Julie A | VP Fin & Admin & CFO | 0 | — | — | 1 | −40.5% (1) | June 14, 2011 |
| Wade M. Andrew | SVP and CFO | 0 | — | — | 1 | +73.8% (1) | December 1, 2017 |
| Young Philip M and related entities | 10% owner | 0 | — | — | 1 | −31.0% (1) | June 7, 2012 |
When several insiders traded Atricure, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Atricure, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 3 buying crowds with six months of prices, it averaged +17.4% against the index. After 9 selling crowds, −0.5%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| July 31, 2026 | 4 selling | +62.2% | not yet | not yet |
| August 29, 2025 | 3 selling | −8.6% | −21.0% | +12.8% |
| June 30, 2021 | 3 selling | −14.5% | −24.3% | −37.9% |
| March 29, 2018 | 2 buying | +28.5% | +57.8% | +22.7% |
| March 31, 2015 | 3 selling | +20.0% | +8.7% | −19.5% |
| June 28, 2013 | 3 selling | +9.6% | +83.5% | +69.1% |
| November 30, 2012 | 3 selling | +9.2% | +20.1% | +99.9% |
| June 29, 2012 | 3 selling | −28.9% | −34.4% | −20.3% |
| March 30, 2012 | 3 selling | −0.6% | −28.5% | −31.2% |
| June 30, 2011 | 6 selling | −9.2% | −10.3% | −30.8% |
| May 31, 2011 | 2 buying | −17.5% | −24.4% | −36.5% |
| March 31, 2011 | 4 selling | +13.3% | +1.3% | −21.0% |